Evan M. Sloane, Ph.D.
Affiliations: | Psychology | University of Colorado, Boulder, Boulder, CO, United States |
Google:
"Evan Sloane"Mean distance: 18.42 (cluster 58) | S | N | B | C | P |
Parents
Sign in to add mentor| Linda R. Watkins | grad student | 2009 | CU Boulder | |
| (Studies of the use of intrathecally delivered interleukin-10 gene therapy for pain control.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Loram LC, Strand KA, Taylor FR, et al. (2015) Adenosine 2A receptor agonism: A single intrathecal administration attenuates motor paralysis in experimental autoimmune encephalopathy in rats. Brain, Behavior, and Immunity. 46: 50-4 |
| Ramos KM, Lewis MT, Morgan KN, et al. (2010) Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disorders. Neuroscience. 169: 1888-900 |
| Soderquist RG, Sloane EM, Loram LC, et al. (2010) Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharmaceutical Research. 27: 841-54 |
| Loram LC, Harrison JA, Sloane EM, et al. (2009) Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 14015-25 |
| Sloane E, Langer S, Jekich B, et al. (2009) Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain. Gene Therapy. 16: 1210-22 |
| Sloane EM, Soderquist RG, Maier SF, et al. (2009) Long-term control of neuropathic pain in a non-viral gene therapy paradigm. Gene Therapy. 16: 470-5 |
| Soderquist RG, Milligan ED, Sloane EM, et al. (2009) PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. Journal of Biomedical Materials Research. Part A. 91: 719-29 |
| Sloane E, Ledeboer A, Seibert W, et al. (2009) Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. Brain, Behavior, and Immunity. 23: 92-100 |
| Loram L, Sholar P, Taylor F, et al. (2009) Adenosine 2A receptor agonist produces long-duration reversal of neuropathic pain via sustained release of spinal interleukin-10 The Journal of Pain. 10: S39 |
| Loram L, Sloane E, Harrison J, et al. (2009) 80. Long-duration reversal of neuropathic pain via sustained release of spinal interleukin-10 is mediated by adenosine 2A receptor activation Brain, Behavior, and Immunity. 23: S47 |